Important update
ReadyCell announces acquisition by MedTech Barcelona, a Leitat Company
In vitro products for drug discovery, adme-tox and transporter research
ReadyCell, Easing your Screening
The leading manufacturer of ready-to-use cell-based plates
ReadyCell provides you with everyday solutions for your in vitro ADME-Tox needs
Permeability Tools
Drug-Transporter Interactions
Blood Brain Barrier
Cytotoxicity
We facilitate and streamline drug discovery and development study assays with available cell-based plates that are stored and transported at room temperature.
Pre-Plated with Patented Medium
Our innovative gel-like shipping medium ensures superior cell quality in our plates and offers a complete solution for in vitro ADME assays.
Worldwide Shipping
Our delivery times are 48-96 hours worldwide. Select your assay date, and we’ll adjust our production and delivery accordingly.
Cost-Saving Assays
Allow your business to respond better to market needs, have a reliable provider of high-quality cell kits, and reduce your capital expenditure.
Do you want to know more about ReadyCell?
From small molecules to biologics and oncological products, ReadyCell is your provider for all your needs. Get to know us and check out client reviews to see our commitment to excellence.
Honoring 20 years of dedication from our team
This year, we had the privilege of celebrating 20 years of dedication from four of our esteemed colleagues—Sheila Guisado, Lourdes Gombau, Alberto Corcho, and Marta Corvo.
Recommended reference compounds for permeability assays
Permeability assays are important for understanding how molecules cross biological barriers, assessing both their ability to cross and the mechanisms involved. While drugs are often absorbed by passive diffusion, some molecules can also be substrates for membrane proteins or transporters.
Caco-2 Permeability Assay Protocol
The permeability assay protocol for Caco-2 cells serves as a cornerstone in understanding and predicting the intestinal absorption of pharmaceutical agents.
ReadyCell announces acquisition by MedTech Barcelona, a Leitat Company
Advancements in β-Glucocerebrosidase modulation: new therapeutics for Gaucher’s Disease
This research, titled Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β‑Glucocerebrosidase, highlights the potential of fragment-based drug discovery (FBDD) and employs permeability assays with CacoReady and PreadyPort plates.
ReadyCell presents the final reporting period of the SEGURAM project
The final presentation highlighted the potential of gut-on-a-chip technology to advance bioavailability and efficacy testing in the meat industry.
Explore our materials of interest
A way to make Europe
European Regional Development Fund
